RBC Capital raises Revolution Medicines price target to $259
RBC Capital raised its price target on Revolution Medicines to $259 from $251, keeping its rating at Outperform, according to a Benzinga report.
Story updates
03:05:47 PM UTC
SquawkNews
Revolution Medicines Price Target Raised to $259.00/Share From $251.00 by RBC Capital